FilingSEC EDGAR8-K
Evommune Secures License for EVO570 and Announces $30 Million Private Placement
· SEC accepted
StageClinical Development
Filing content
Evommune secured exclusive rights to the VAV1 degrader EVO570 from Hinova and announced a $30 million private placement of common stock.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…